ALLMedicine™ Cholangiocarcinoma Center

Jan 20th, 2021 - A detailed understanding of the molecular alterations in different forms of cholangiocarcinogenesis is crucial for a better understanding of cholangiocarcinoma (CCA) and may pave the way to early diagnosis and better treatment options. We analysed...

Jan 20th, 2021 - The objective of this study was to investigate the benefits of adjuvant treatment for patients with resected perihilar cholangiocarcinoma (PHC). Between 2001 and 2017, 196 patients with PHC adenocarcinoma underwent curative resection. The patients...

Jan 20th, 2021 - The clinical importance of peritoneal washing cytology (PWC) for cholangiocarcinoma patients remains unclear. The clinical data of 137 extrahepatic cholangiocarcinoma patients who received PWC and curative surgery were retrospectively analyzed. Am...

Jan 20th, 2021 - Cholangiocarcinoma (CCA) is a fatal disease with dismal survival rates. Long non-coding RNA (lncRNA) expression profiling as potential prognostic biomarkers play critical roles in tumor initiation, development, and poor prognosis. Identifying spec...

Jan 19th, 2021 - Intrahepatic cholangiocarcinoma had been considered a contraindication for liver transplantation because of poorer outcomes. However, incidental intrahepatic cholangiocarcinoma in the explanted liver has been reported because of the difficulty of ...

Jul 15th, 2019 - The purpose of this clinical practice update is to define key principles in the surveillance of hepatobiliary cancers including cholangiocarcinoma, gallbladder adenocarcinoma, and hepatocellular carcinoma in patients with primary sclerosing cholan...

Mar 10th, 2019 - PURPOSE To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with resected biliary tract cancer. METHODS ASCO convened an Expert Panel to conduct a systematic review of the literature on adju...

Dec 23rd, 2018 - IgG4-related sclerosing cholangitis (IgG4-SC) is a distinct type of cholangitis frequently associated with autoimmune pancreatitis and currently recognized as a biliary manifestation of IgG4-related disease. Although clinical diagnostic criteria o...

Jul 14th, 2015 - An American Hepato-Pancreato-Biliary Association (AHPBA)-sponsored consensus meeting of expert panellists met on 15 January 2014 to review current evidence on the management of hilar cholangiocarcinoma in order to establish practice guidelines and...

Jan 28th, 2013 - Hilar cholangiocarcinoma (HCCA) is one of the most common types of hepatobiliary cancers reported in the world including Asia-Pacific region. Early HCCA may be completely asymptomatic. When significant hilar obstruction develops, the patient prese...

Jan 20th, 2021 - A detailed understanding of the molecular alterations in different forms of cholangiocarcinogenesis is crucial for a better understanding of cholangiocarcinoma (CCA) and may pave the way to early diagnosis and better treatment options. We analysed...

Jan 20th, 2021 - The objective of this study was to investigate the benefits of adjuvant treatment for patients with resected perihilar cholangiocarcinoma (PHC). Between 2001 and 2017, 196 patients with PHC adenocarcinoma underwent curative resection. The patients...

Jan 20th, 2021 - The clinical importance of peritoneal washing cytology (PWC) for cholangiocarcinoma patients remains unclear. The clinical data of 137 extrahepatic cholangiocarcinoma patients who received PWC and curative surgery were retrospectively analyzed. Am...

Jan 20th, 2021 - Cholangiocarcinoma (CCA) is a fatal disease with dismal survival rates. Long non-coding RNA (lncRNA) expression profiling as potential prognostic biomarkers play critical roles in tumor initiation, development, and poor prognosis. Identifying spec...

Jan 19th, 2021 - Intrahepatic cholangiocarcinoma had been considered a contraindication for liver transplantation because of poorer outcomes. However, incidental intrahepatic cholangiocarcinoma in the explanted liver has been reported because of the difficulty of ...

Apr 19th, 2020 - The US Food and Drug Administration (FDA) has granted accelerated approval of a new targeted therapy for use in some patients with cholangiocarcinoma, a rare cancer of the bile ducts. The product is pemigatinib (Pemazyre, Incyte), an oral kinase i...

Apr 19th, 2020 - The US Food and Drug Administration (FDA) has granted accelerated approval of a new targeted therapy for use in some patients with cholangiocarcinoma, a rare cancer of the bile ducts. The product is pemigatinib (Pemazyre, Incyte), an oral kinase i...

Feb 19th, 2020 - Cancer of the bile duct, or cholangiocarcinoma, is a malignant neoplasm of the intrahepatic or extrahepatic biliary epithelium. It is the most common biliary tract cancer and the second most common primary hepatic cancer. Although its etiology is ...

Feb 19th, 2020 - Figure 1. Common bile duct and pancreatic duct Perihilar tumors, also called Klatskin tumors, are the most common cholangiocarcinomas. They occur in the hilum region at the bifurcation of the right and left hepatic ducts. Intrahepatic tumors are t...

Feb 19th, 2020 - Even though the rates of resection with tumor-free margins have improved with more aggressive surgical approaches and improved radiologic techniques, recurrence rates remain high (49%-64%). These recurrences usually occur within 2-3 years post-res...